SCHEMBL19283672

SCHEMBL19283672

COCCNC(=O)CC(Nc1nc2ccccc2[nH]1)c1cccc(OC(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 1/20 0.47
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ RAB9A P51151 7/20 0.43
▸ NPC1 O15118 6/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ PKM P14618 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.40
▸ MET P08581 1/20 0.40
▸ CDK9 P50750 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ GPR139 Q6DWJ6 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ ALOX12 P18054 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19283580 0.92 MTOR (0.46) MTORMEN1KMT2ARAB9ANPC1
SCHEMBL19283561 0.89 ITGA5 (0.45) MTORMEN1KMT2ARAB9ANPC1
SCHEMBL19283638 0.88 MTOR (0.46) MTORMEN1KMT2ARAB9ANPC1
SCHEMBL20743025 0.88 MTOR (0.49) MTORMEN1KMT2ARAB9ANPC1
SCHEMBL19283684 0.87 HPGD (0.41) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL21821314 0.84 RAB9A (0.47) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL19283571 0.83 HPGD (0.44) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL20764736 0.82 MTOR (0.48) MTORMEN1KMT2ARAB9ANPC1
SCHEMBL30410997 0.82 MTOR (0.48) MTORMEN1KMT2ARAB9ANPC1
SCHEMBL19283499 0.82 ITGA5 (0.45) MTORMEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US claimed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US claimed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN claimed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP claimed
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN disclosed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP disclosed
EP-3419973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2019-01-02 — — EP disclosed
WO-2017144183-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2017-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNJ2, KCNN2, KCNN1 MTOR 1774/4885MEN1 1978/4885KMT2A 1923/4885
US-11274092-B2 Potassium channel inhibitors KCNJ2, KCNJ11, KCNJ1 MTOR 2223/4885MEN1 1357/4885KMT2A 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback